Page last updated: 2024-11-13

1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1h-benzotriazole-5-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

The compound you're describing, 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid, is not a commonly known or studied compound. It's possible that there is a typographical error in the name, or it may be a novel compound that hasn't been characterized extensively.

**Here's why it's difficult to determine its importance for research without more information:**

* **Lack of Common Name or CAS Number:** Without a common name or Chemical Abstracts Service (CAS) number, it's difficult to find research papers or databases that mention it.
* **Complex Structure:** The name suggests a complex structure with multiple substituents and a fused ring system. This type of structure is often found in compounds with interesting biological activity.
* **Potential Applications:** Without understanding the specific properties of the compound, it's impossible to say if it has potential applications in research areas like pharmaceuticals, materials science, or other fields.

**To understand its importance, you would need to:**

1. **Verify the Name:** Double-check the spelling and chemical structure of the compound to ensure it's correct.
2. **Search Databases:** Search databases like PubChem, SciFinder, or Reaxys using the correct name or structure to see if it has been previously reported.
3. **Identify Potential Uses:** Based on the chemical structure and any available information, try to identify potential applications or research areas where it could be relevant.

**It's important to note that without more information, it's impossible to definitively assess the importance of this compound for research.**

1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid: a partial RXR agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71461789
CHEMBL ID2146901
SCHEMBL ID17053789
MeSH IDM0584673

Synonyms (6)

Synonym
CHEMBL2146901 ,
bdbm50391814
SCHEMBL17053789
1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1h-benzotriazole-5-carboxylic acid
9hf ,
1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)benzotriazole-5-carboxylic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Treating insulin resistance and type 2 diabetes in rodents, currently known retinoid X receptor (RXR) agonists induce significant adverse effects."( RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
Fujiwara, C; Hagaya, M; Kakuta, H; Kawata, K; Maehara, A; Makishima, M; Nakayama, M; Ohsawa, F; Ohta, Y; Oohashi, T; Shinozaki, R; Tai, A; Uno, S; Yakushiji, N; Yamada, S; Yasui, H; Yoshikawa, Y, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Retinoic acid receptor RXR-alphaHomo sapiens (human)EC50 (µMol)0.14300.00010.34279.1000AID1633899; AID689341; AID730299
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (64)

Assay IDTitleYearJournalArticle
AID689515Downregulation of G6p mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689359Toxicity in male Sprague-Dawley rat assessed as change in water intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689372Toxicity in KK-Ay mouse assessed as increase in body weight at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID730286Partial agonist activity at mouse RXRalpha expressed in COS1 cells by luciferase reporter gene assay relative to bexarotene2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID1633895Toxicity in fertilized zebra fish embryos assessed as survival rate at 1000 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689353Drug level in ICR mouse serum at 30 mg/kg, po2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633901Aqueous solubility in pH 7.4 PBS buffer at 1 mM after 6 hrs by HPLC analysis2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689361Toxicity in male Sprague-Dawley rat assessed as change in food intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689516Downregulation of Pck mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689360Toxicity in female Sprague-Dawley rat assessed as change in water intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID730302Transactivation of RXRalpha (unknown origin) expressed in COS1 cells at 10 uM after 18 hrs by luciferase reporter gene assay relative to bexarotene2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID689341Partial agonist activity at RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633900Agonist activity at human RXRalpha expressed in African green monkey COS1 cells harboring CRBP2-tk-luc reporter incubated for 18 hrs by steady-glo luciferase reporter gene assay relative to control2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689365Toxicity in female Sprague-Dawley rat assessed as change in serum constituents at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633894Toxicity in fertilized zebra fish embryos assessed as survival rate at 300 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689369Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as reduction in HbA1c level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689352Agonist activity at LXRalpha/RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689356Toxicity in ICR mouse assessed as increase in serum triglyceride level at 30 mg/kg/day, po for 7 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689349Agonist activity at PPARgamma expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633896Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 100 nM after 120 hrs post fertilization by microscopic method relative to control2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689520Upregulation of Srebp1c mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633898Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 1000 nM after 120 hrs post fertilization by microscopic method relative to control2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689351Agonist activity at LXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689371Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as increase in adiponectin level at 10 mg/kg/day, po administered for 14 days by oral glucose tolerance test2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633888Toxicity in fertilized zebra fish embryos assessed as hatching rate at 100 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689362Toxicity in female Sprague-Dawley rat assessed as change in food intake at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633890Toxicity in fertilized zebra fish embryos assessed as hatching rate at 300 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID730297Partial agonist activity at human RXRalpha expressed in Escherichia coli BL21AI assessed as recruitment of fluorescent-labeled coactivator D22 at 10 uM after 1 hr by fluorescence polarization assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID730300Transactivation of RXRalpha (unknown origin) expressed in COS1 cells at 0.1 uM after 18 hrs by luciferase reporter gene assay relative to bexarotene2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID689363Toxicity in male Sprague-Dawley rat assessed as enlarged testes at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689347Transactivation of RARbeta expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689513Upregulation of Slc2a1 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689354Toxicity in ICR mouse assessed as increase in body weight at 30 mg/kg/day, po for 7 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689355Toxicity in ICR mouse assessed as increase in liver weight at 30 mg/kg/day, po for 7 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689357Toxicity in male Sprague-Dawley rat assessed as change in body weight at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689348Transactivation of RARgamma expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689358Toxicity in female Sprague-Dawley rat assessed as change in body weight at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID730285Partial agonist activity at human RXRalpha by luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID689343Partial agonist activity at RXRbeta expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689374Toxicity in KK-Ay mouse assessed as increase in serum triglyceride level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID730301Transactivation of RXRalpha (unknown origin) expressed in COS1 cells at 1 uM after 18 hrs by luciferase reporter gene assay relative to bexarotene2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID689344Partial agonist activity at RXRgamma expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633897Toxicity in fertilized zebra fish embryo assessed as teratogenic effect by measuring malformation of spine curvature and head enlargement at 300 nM after 120 hrs post fertilization by microscopic method relative to control2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689345Partial antagonist activity at RXRalpha expressed in human Cos1 cells assessed as reduction in LGD1069-induced luciferase activity after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689517Upregulation of Gck mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689518Upregulation of Fasn mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633899Agonist activity at human RXRalpha expressed in African green monkey COS1 cells harboring CRBP2-tk-luc reporter incubated for 18 hrs by steady-glo luciferase reporter gene assay2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689346Transactivation of RARalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689375Toxicity in KK-Ay mouse assessed as increase in total cholesterol level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID730298Partial agonist activity at RXRalpha (unknown origin) expressed in COS1 cells after 18 hrs by luciferase reporter gene assay relative to bexarotene2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID689370Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as increase in glucose tolerance at 10 mg/kg/day, po administered for 14 days by oral glucose tolerance test2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID730299Partial agonist activity at RXRalpha (unknown origin) expressed in COS1 cells after 18 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Mechanism of retinoid X receptor partial agonistic action of 1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-1H-benzotriazole-5-carboxylic acid and structural development to increase potency.
AID689342Partial agonist activity at RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay relative to 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689514Upregulation of Slc2a2 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689373Toxicity in KK-Ay mouse assessed as increase in liver weight at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689376Upregulation of Irs1 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689368Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as reduction in serum insulin level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689364Toxicity in male Sprague-Dawley rat assessed as change in serum constituents at 30 mg/kg/day, po for 28 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689512Upregulation of Irs2 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID1633891Toxicity in fertilized zebra fish embryos assessed as hatching rate at 1000 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID1633892Toxicity in fertilized zebra fish embryos assessed as survival rate at 100 nM incubated for 120 hrs post fertilization by microscopic method relative to untreated control (Rvb = 100%)2019Bioorganic & medicinal chemistry letters, 08-01, Volume: 29, Issue:15
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity.
AID689367Antidiabetic activity in diabetic, obese KK-Ay mouse assessed as reduction in blood glucose level at 10 mg/kg/day, po administered for 14 days relative to vehicle-treated control2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689519Upregulation of Scd1 mRNA expression in KK-Ay mouse liver at 10 mg/kg/day, po administered for 14 days by RT-PCR analysis2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
AID689350Agonist activity at PPARgamma/RXRalpha expressed in human Cos1 cells after 18 hrs by SEAP reporter gene assay2012ACS medicinal chemistry letters, May-10, Volume: 3, Issue:5
RXR Partial Agonist CBt-PMN Exerts Therapeutic Effects on Type 2 Diabetes without the Side Effects of RXR Full Agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]